Stay updated on Esom/Rifampin Safety, PK and Alisertib QT Clinical Trial
Sign up to get notified when there's something new on the Esom/Rifampin Safety, PK and Alisertib QT Clinical Trial page.
Latest updates to the Esom/Rifampin Safety, PK and Alisertib QT Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoNo Change Detected
- Check20 days agoChange DetectedA new consolidated Locations section lists participating sites by state (Florida, Missouri, Oklahoma, Tennessee, Texas, Wisconsin) and the prior state-specific location subsections have been removed.SummaryDifference0.7%
- Check28 days agoNo Change Detected
- Check49 days agoChange DetectedRevision updated to v3.3.2. The previous revision v3.2.0 was removed.SummaryDifference0.1%
- Check56 days agoChange DetectedRemoved a general government funding and operating status notice from the page, which previously informed users that information may not be up to date and that the NIH Clinical Center is open. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%
- Check70 days agoChange DetectedNo notable additions or deletions were detected; the page content and layout appear unchanged. The study details, eligibility criteria, and locations remain the same as in the previous view.SummaryDifference0.3%
- Check99 days agoChange DetectedThe page now explicitly notes potential delays due to funding, confirms the NIH Clinical Center is open, directs users to cc.nih.gov and opm.gov for status, and indicates a version upgrade to v3.2.0.SummaryDifference3%
- Check106 days agoChange DetectedChanged the revision from v3.0.2 to v3.1.0, indicating a minor version update with no other content changes.SummaryDifference0.1%
Stay in the know with updates to Esom/Rifampin Safety, PK and Alisertib QT Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Esom/Rifampin Safety, PK and Alisertib QT Clinical Trial page.